WB
H
Endogenous
213
Rabbit
#Q2TAZ0
23130
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu750 of human Atg2A protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Autophagy is a catabolic process that results in the degradation of bulk cytoplasmic contents within autophagosomes and lysosomes. The control of autophagy involves proteins encoded by a set of autophagy-related genes (Atg) that were originally characterized in yeast (1). Research studies in yeast indicate that Atg2 is essential for autophagy and the retrograde transport of Atg9 through an interaction with Atg18 (2-6). Two human Atg2 homologs (Atg2A, Atg2B) are critical for autophagosome formation as silencing of both results in the accumulation of unclosed autophagic structures (7). Starvation-induced autophagy targets Atg2A to the initiation site of autophagosome biogenesis, where it associates with DFCP1, WIPI-1, and other autophagy-related proteins (8).
Atg2 proteins also function in lipid droplet metabolism as depletion of both Atg2A and AtgB results in changes in the size, number, and distribution of lipid droplets (7,8). These morphological changes in lipid droplets are not observed in Atg5-depleted cells, suggesting that this function is independent of the role of Atg2 in autophagy (7). Starvation-induced autophagy directs Atg2A (along with Atg14L) to localize to early autophagosomal membranes enriched in PI3P, while another subpopulation of Atg2A and Atg14L localizes to the lipid droplets independent of autophagic status (8). An increase in Atg2A expression during etoposide- and doxorubicin-induced apoptosis suggests that Atg2A may be a useful indicator of topoisomerase II inhibitor-mediated apoptosis (9). Mutations in the corresponding Atg2B gene are associated with gastric and colorectal carcinomas with high microsatellite instability (10).
- Reggiori, F. and Klionsky, D.J. (2002) Eukaryot Cell 1, 11-21.
- Shintani, T. et al. (2001) J Biol Chem 276, 30452-60.
- Wang, C.W. et al. (2001) J Biol Chem 276, 30442-51.
- Suzuki, K. et al. (2001) EMBO J 20, 5971-81.
- Obara, K. et al. (2008) J Biol Chem 283, 23972-80.
- Reggiori, F. et al. (2004) Dev Cell 6, 79-90.
- Velikkakath, A.K. et al. (2012) Mol Biol Cell 23, 896-909.
- Pfisterer, S.G. et al. (2014) J Lipid Res 55, 1267-78.
- Kusama, Y. et al. (2009) Apoptosis 14, 1165-75.
- Kang, M.R. et al. (2009) J Pathol 217, 702-6.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.